N/A N=88 Treatment

Use of Norethindrone Acetate for Management of Bleeding Associated With the Etonogestrel Contraceptive Implant

Etonogestrel Contraceptive Implant, Bothersome Bleeding

Bottom Line

View on ClinicalTrials.gov: NCT02353247 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Mar 2022

Primary outcome: Primary: Impact of Aygestin (and Dose of Aygestin) on the Management of Bothersome Bleeding Associated With the Etonogestrel Contraceptive Implant — 2.73; 2.77; 2.76; 2.27 units on a scale

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Norethindrone acetate (Drug)
Age: Pediatric, Adult, Older Adult
Sex: Female
Sponsor: Norton Healthcare
Primary completion: Jun 2017

Outcome Measures

Outcome	Result	p-value
PRIMARY Impact of Aygestin (and Dose of Aygestin) on the Management of Bothersome Bleeding Associated With the Etonogestrel Contraceptive Implant	2.73; 2.77; 2.76; 2.27; 2.65; 2.67	—

Summary

The overall objective of this study is to confirm that oral progesterone is an effective way to manage bothersome bleeding; thus increasing the rate of continuation of the etonogestrel contraceptive implant in adolescents.

Eligibility Criteria

Inclusion Criteria

Inclusion criteria will include any post---menarchal female presenting to the Kosair Children's Hospital Gynecologic Specialist practice, who desires to use the etonogestrel contraceptive implant and has access to a mobile phone device.

Exclusion Criteria

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02353247). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.